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AbSTRACT:  Preparation  for  the  fiftieth  anniversary  of  human  spaceflight  in  the 
spring of 2011 provides the space faring nations with an opportunity to reflect on 
past achievements as well as consider the next fifty years of human spaceflight. 
The International Space Station is a unique platform for long duration life science 
research that will play a critical role in preparing for future human space exploration 
beyond low earth orbit. Some feel the future path back to the Moon and on to Mars 
may be delayed with the current commitment of the united States to support the 
development of human-rated commercial spacecraft. others see this as a unique 
opportunity to leverage the capability of the private sector in expanding access to 
space exploration. This article provides an overview of the past achievements in hu-
man spaceflight and discusses future missions over the next fifty years and the role 
space medicine will play in extending the time-distance constant of human space 
exploration.
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  The past five decades will stand for eternity 
as that period in history when humans became a 
space faring species. From the first flights of Yuri 
Gagarin and Alan Shepard in the spring of 1961 to 
the Apollo 11 lunar landing in 1969, people through-
out the world were mesmerized by the incredible 
progress of space exploration. The decade culmi-
nated with the achievement of President Kennedy’s 
vision of human exploration of the lunar surface and 
safe return to Earth. Meeting this goal required the 
combination of sophisticated engineering, life sci-
ence and medical research with a dedicated team 
committed to making what appeared impossible, 
possible. 
  From a clinical perspective, bioastronautics 
(1) and space medicine (2) (3) research demon-
strated that humans could survive in space, work in 
space and perform complex scientific missions on 
the surface of another celestial body. After the ex-
ponential growth in short duration flight objectives 
of the sixties, the past four decades have focused 
on the development of a long duration capability for 
human spaceflight. The vision of sending humans 
farther into the solar system was shared by many 
experts within the United States and Russia. For 
that vision to become reality, the acclimation of hu-
mans to space had to be studied over the course 
of months not days. The Russian Salyut series of 
space stations and the NASA Skylab (4) (5) (6) pro-
gram that highlighted the next decade of human 
spaceflight were used to evaluate the capacity of 
humans to live and work in microgravity for long pe-
riods of time. Both programs provided fundamen-
tal data on space physiology (7) relevant to space 
medicine, but they also demonstrated the need for 
extended long duration missions on board a new 
generation of space stations.
  The scientific utilization of space stations 
as microgravity research platforms provided an 
additional technical challenge in developing the 
capability to bring payloads to and from low earth 
orbit. The Space Shuttle was designed to meet this 
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unique requirement along with additional roles as 
an autonomous science platform and as a vehicle 
that could be used to launch and repair satellites. 
The need for onboard robotics as a critical enabling 
technology was identified and Canada was invited 
to design and produce a robotic arm for the Shut-
tle program. Referred to as the Canadarm, or “the 
arm” for short, this contribution to the Shuttle pro-
gram led to the first selection of six Canadian astro-
nauts in 1983, with the prospect of a series of three 
flights for Canadian scientist astronauts referred to 
by NASA as payload specialists. Twenty-five years 
ago, Mark Garneau became the first Canadian to 
fly in space aboard the Space Shuttle Challenger. 
A number of dedicated Canadian experiments were 
selected  for  the  STS-41G  mission,  creating  an 
opportunity for Canadian scientists to obtain first-
hand experience with microgravity research. These 
experiments were referred to with the acronym 
CANEX, a descriptor which was used for the re-
maining two flights of Canadian payload specialists 
that took place in 1992. 
  By this time, the concept of a partnership of 
the major space faring nations working together to 
create a world-class orbiting research platform had 
become a reality, and the newly emerging space 
station program led to the need for, and selection of 
a second group of Canadian astronauts. During a 
six-month selection process, the Canadian Space 
Agency used a complex set of selection criteria to 
hire four new astronauts that would train as mis-
sion specialists for long duration missions on board 
the space station. Roberta Bondar and her back-up 
Ken Money retired after participating in the Inter-
national Microgravity Laboratory (IML-2) mission in 
January 1992, leaving Marc Garneau, Bob Thirsk, 
Bjarni Tryggvason and Steve Maclean to be joined 
by Chris Hadfield, Julie Payette, Mike McKay and 
Dave Williams for mission specialist training and 
potential assignment to shuttle flights or space sta-
tion construction missions. This was a pivotal time 
for the Canadian Space Agency that had raised the 
Canadian profile as a major space faring nation, 
now with an expanded team of 8 astronauts, two 
with mission experience, capable of leveraging the 
Canadian robotic and scientific expertise. 
  The initial design requirements for the pro-
posed space station included a health maintenance 
facility (HMF) (8) in recognition of the potential medi-
cal issues that could arise during long duration mis-
sions in low earth orbit. In addition to the HMF, the 
proposed airlock design provided both a hypobaric 
capability necessary for suited astronauts to egress 
the station for spacewalks as well as a hyperbaric 
capability to treat potential episodes of decom-
pression sickness (DCS) that could arise during a 
space walk. The designated operating pressure of 
the space station was 1 atmosphere (14.7 p.s.i.), 
similar to that of the Space Shuttle, while the suit 
pressure of the extravehicular mobility unit (EMU) 
was 4.3 p.s.i. thereby introducing the risk of DCS 
while transitioning to the lower suit pressure. De-
spite the rigorous design requirements for on board 
healthcare, these facilities were not implemented in 
the construction of the International Space Station 
primarily due to cost constraints.
  Historically, during the Shuttle era, the clini-
cal approach to prevention, diagnosis and treat-
ment of illness and injury in space had a strong 
emphasis on prevention. This was accomplished 
through medical selection criteria, regular medical 
screening, and the development of countermea-
sures to mitigate the many physiologic changes 
associated with exposure to microgravity. This ap-
proach evolved from the early work in the Mercury, 
Gemini and Apollo programs that was based pri-
marily on a preventive strategy with rudimentary on 
orbit diagnostic and treatment capabilities based on 
the use of small medical kits with support from flight 
surgeons in mission control. The Skylab program 
provided an excellent opportunity for biomedical re-
search during long duration missions that helped 
further delineate the physiologic changes associ-
ated with exposure to microgravity. These results 
were used to develop the exercise, cardiovascular 
and neurovestibular countermeasures implement-
ed in the early Shuttle program and led to a further 
series of life science experiments conducted on 
dedicated Shuttle research missions. These stud-
ies were concluded by the launch of the first ele-
ment of the International Space Station (ISS) in the 
fall of 1998 and were published a year later as a 
comprehensive extended duration orbiter medical 
project (EDOMP) (9) (10).
  Canadian researchers participated in 
a number of collaborative Shuttle experiments 
throughout this time to help understand the many 
physiologic changes associated with acclimation to 
microgravity and to evaluate potential preventive 
countermeasures. In addition, researchers at the 
Canadian Space Agency (CSA) worked in collabo-
ration with experts in DCS at the Defence Research 
and Development Canada Centre in Toronto to par-
ticipate as one of three NASA supported research 
sites to develop the new pre-breathe protocols for 
use in preparation for spacewalks from the Interna-
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  The future of human spaceflight will likely 
include increased accessibility and utilization of low 
earth orbit for commercial ventures and continued 
use of the ISS, ultimately leading to a transition back 
to exploration missions potentially involving lunar 
return or missions to Mars. The need to further de-
velop mission-specific medical capability involves 
discussions of the balance between the need for 
a “stand-and-fight” capability and the utilization of 
a “load-and-go” approach to returning to Earth for 
definitive  medical  care.  Currently  approaches  to 
on orbit health care use both approaches with the 
combination of immediate clinical care combined 
with the potential for an urgent or emergent deorbit 
and landing for definitive medical care. As humans 
travel farther into space, a medical abort to Earth 
scenario becomes less practical and at some point 
transitions  to  continued  flight  to  the  destination. 
This raises a number of questions about defining 
the appropriate level of care, the effect of longer 
signal transmission to Earth on crew autonomy and 
the role that new technologies will play in the deliv-
ery of healthcare during the different phases of the 
mission.
  On the ISS, as the complexity of medical 
interventions increases, there is greater reliance on 
ground expertise through the use of telemedicine, 
a fundamental component of linking the flight sur-
geon in mission control to the CMO for health care 
delivery in space (19). Telemedicine is the use of 
information and communication technology in near 
real-time to support medical providers at a dis-
tance. Many attempts have been made to evaluate 
and validate various protocols in extreme and re-
mote environments that replicate the resource defi-
cient and psychologically demanding conditions of 
human spaceflight (20). This has included a range 
of procedures from telementor-guided ultrasound 
to remotely operated surgical robotics (21) (22). As 
human space exploration extends further out into 
the solar system, the latency of communication will 
pose significant challenges to the remote medical 
support of health care delivery in space. 
  Planning for future exploration class mis-
sions should include characterizing the impact of 
communication delay with existing telemedicine 
technology on real-time flight surgeon CMO coordi-
nation, defining the future skill sets and training re-
quirements for CMOs, as well as expanding the cur-
rent capabilities to meet the future needs for space 
medical systems. For this reason, a comprehensive 
assessment of the likelihood and impact of poten-
tial medical conditions should be conducted based 
nostic ultrasound protocols but is also available for 
clinical diagnostic use as needed. The portability 
and ease of use of diagnostic ultrasound have led 
to its adoption as the diagnostic imaging modality 
of choice in space. With current technology, other 
diagnostic imaging (DI) technologies are not practi-
cal for use in space. Further research on the role 
of diagnostic ultrasound and the development of 
alternative DI technologies is as important as an 
exploration enabling capability for future missions 
beyond low earth orbit. 
  Current on-board laboratory investigations 
are limited compared to terrestrial medicine. A num-
ber of research projects focus on developing por-
table blood analyzers (http://www.nsbri.org/News-
PublicOut/Release.epl?r=89) that will be a valuable 
adjunct to both researchers and clinicians in the 
future. In the interim, flight surgeons rely heavily 
upon a clinical history and physical examination to 
formulate a differential and primary diagnosis.
  Past research efforts have focused on un-
derstanding the physiologic acclimation to micro-
gravity with the development of a series of preven-
tive countermeasures leading to further work that 
will continue to improve this preventive strategy. 
However, there is a tremendous amount of clini-
cal research that is needed. The pharmacokinet-
ics of drug use in microgravity and partial gravita-
tional environments is an important area of further 
research (15) (16) while the effects of spaceflight 
on the pathophysiology of disease are either the 
subject of speculation or largely unknown. Building 
on the known physiologic acclimation to space, the 
pathophysiology of different diseases in space may 
be predictable, but some illnesses such as DCS 
may be fundamentally different in microgravity (17). 
  For the most part, therapeutic interven-
tions in space involve the administration of medica-
tions orally, intramuscularly or intravenously. Foley 
catheters have been inserted for isolated cases of 
urinary retention (18) and intravenous access has 
been used for research studies and for some clini-
cal interventions. There are no reported cases of 
wound repair using sutures or wound cement in 
humans, but anecdotal reports following animal 
surgery suggest that successful wound healing 
takes place with the use of wound cement. While a 
number of studies of more advanced medical and 
surgical interventions have been evaluated in para-
bolic flight, further research and documentation of 
microgravity techniques for common interventions 
is warranted.
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to those used in commercial aviation with the ad-
ditional stipulation that prospective SFPs sign an 
informed consent prior to flight (CFR 14 Part 460) 
([NO STYLE for: ]). The FAA does not have a man-
date to regulate passenger health or preflight medi-
cal screening on the proposed commercial space-
flights. Guidelines for screening SFPs have been 
published by the international space medicine com-
munity (12), yet it is uncertain whether or not com-
mercial operators will implement them. Career as-
tronauts utilizing commercial spacecraft to access 
low earth orbit will likely be governed by preflight 
screening and a quarantine process similar to cur-
rently used protocols, yet this also remains to be 
determined.
  Despite rigorous screening programs, the 
increased size of the ISS crew coupled with the 
long duration missions and the increasing frequen-
cy of flights by SFPs suggests that the frequency 
of on-orbit medical events may increase. While the 
majority of these events include space adaptation 
syndrome, motion sickness, back pain, musculo-
skeletal problems and disrupted sleep, the poten-
tial for a more significant medical event exists. For 
this reason, there has been considerable interest 
and research in developing and testing innovative 
diagnostic and therapeutic modalities over the past 
decade that will continue throughout ISS utilization.
  The current paradigm for provision of 
healthcare on the ISS is based on dedicated crew 
medical officers (CMOs) utilizing the resources of 
the Crew Health Care System (CHeCS) to prevent, 
diagnose and treat on orbit medical events. A num-
ber of integrated medical kits are available on the 
ISS to treat the common medical problems that 
arise in space as outlined in the Integrated Medical 
Group medical operations checklist for expedition 
flights. In some cases the CMO is a physician, but 
for the most part, they are crew members that have 
received additional medical training in preparation 
for the mission. CMOs provide care under the di-
rection of Flight Surgeons in mission control based 
on voice/video private medical conferences. This 
approach has been extremely effective in manag-
ing the medical events that have taken place in 
space.
  Additional equipment exists on the ISS 
to augment the CHeCS capability. The Human 
Research Facility - 1 (HRF-1) is equipped with a 
space-adapted, rack-mounted version of the HDI-
5000  Ultrasound  System  (ATL/Philips,  Bothwell, 
WA). This unit has been used for a number of re-
search studies (13) (14) evaluating various diag-
tional Space Station. This led to widespread recog-
nition among the international partners of Canadian 
expertise in life science and space medicine re-
search, which has continued into the current phase 
of ISS utilization.
  The first twenty missions to the ISS were 
made up of three international crew members living 
aboard for approximately six months. Last year the 
crew configuration was extended to the original de-
sign requirement to accommodate six crew mem-
bers for long duration missions thereby extending 
the capability to utilize the station as a research 
platform. During crew rotation Shuttle missions 
the number of crew increases to up to 13 during 
docked operations. With increased utilization, the 
probability of an on board medical event increases. 
While the preventive approach to reducing the risk 
of significant illness and injury has been effective, 
some believe it is a matter of time before there is a 
medical emergency in space. In addition to the ca-
reer astronauts and cosmonauts living and working 
in space, a new generation of space flight partici-
pants (SFPs), or space tourists, have been visiting 
the space station since 2001. 
  Extending the opportunity to visit the ISS to 
space tourists challenged the space medicine com-
munity to decide whether or not a similar approach 
to pre-flight medical screening would be used for 
the SFPs. While these individuals were paying mil-
lions of dollars for the privilege of visiting the ISS, 
a significant on board medical event could have a 
profound mission impact and it was decided that 
a pre-flight medical assessment was needed as a 
risk mitigation strategy. Seven SFPs have visited 
the ISS the most recent being Guy Laliberte from 
Canada, and to date no significant medical events 
have been reported.
  Space medicine can be defined as the area 
of medical practice that deals with the provision of 
healthcare in partial and microgravitational envi-
ronments. The scope of care not only deals with 
the prevention, diagnosis and treatment of illness 
and injury in space, it involves pre-flight medical 
selection and conditioning as well as post-flight re-
habilitation. The expansion of commercial space 
operations to include SFPs and potentially career 
astronauts flying on commercial spacecraft in sub-
orbital and orbital flights presents a number of po-
tential issues to the space medicine community. The 
FAA has released a series of requirements for crew 
and SFPs on commercial spacecraft in support of 
the Commercial Space Launch Amendments Act 
of 2004. These requirements are similar in nature 80 Human Space Exploration 2011 81 Vol. 13 No. 2
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on a combination of historical data, expert opinion, 
analogue studies and epidemiological studies from 
other related high-risk occupations (23) to facilitate 
development of future medical protocols.
  Unfortunately, the rarity and complexity of 
medical illness during spaceflight makes it difficult 
to evaluate the effectiveness of these protocols and 
new  medical  technologies.  High-fidelity  medical 
simulation has been suggested as an effective tool 
to assess the performance of high-level medical 
systems and interdependent medical teams (24). 
Electromechanical robotic mannequins can be 
used to simulate a wide variety of physiologic pa-
rameters, medical emergencies and illnesses in a 
controlled, reproducible, and risk-free environment 
to evaluate clinical protocols. Beyond research and 
testing, medical simulation is also an ideal platform 
for providing medical education and training oppor-
tunities for CMOs who may not be exposed to the 
required breadth of clinical experience necessary 
for supporting a space mission. In addition, it pro-
vides a context-specific opportunity for CMOs skill 
retention during a mission, or to provide just-in-time 
medical  training  to  deal  with  an  in-flight  medical 
emergency. 
  The next decade provides an opportunity 
for further ISS research to develop new diagnostic 
and treatment capabilities, assess new technolo-
gies and evaluate strategies for CMO skill reten-
tion and just-in-time training. This research will be 
important to prepare for exploration class missions 
beyond low earth orbit in addition to developing on 
board clinical care for commercial space complex-
es. Based on the terrestrial approach of providing 
on-board healthcare for commercial ocean cruises, 
it is likely that commercial space complexes will 
have an on-board clinic with a physician or other 
health care professional providing clinical care. The 
evolution of commercial space travel in the decades 
to come will extend the scope of space medicine 
beyond the realm of the government supported 
human spaceflight into the realm of civilian space-
flight. While the objectives of human space travel 
will differ between the government and commercial 
groups, there will be a shared interest amongst 
practitioners of space medicine in developing the 
best approaches to prevent and treat illnesses and 
injuries during a mission. Clearly, the future oppor-
tunities for those interested in space medicine are 
very exciting.
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